Naveen Pemmaraju
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Naveen Pemmaraju as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:20 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07128381 · Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center · recruiting · Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) · principal investigator
- Ph1NCT06613217 · Study of Oral PCLX-001 in R/R Acute Myeloid LeukemiaPacylex Pharmaceuticals · recruiting · Relapsed Adult AML · principal investigator
- Ph2NCT04216524 · Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmM.D. Anderson Cancer Center · recruiting · Blastic Plasmacytoid Dendritic Cell Neoplasm · principal investigator
- Ph1NCT04022785 · PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm · principal investigator
- Ph2NCT02098161 · LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisM.D. Anderson Cancer Center · completed · Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT04216524, NCT04022785
Most cited trial papers
Clinical-trial papers with this author name in chronic myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:20 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- 221 citationsRCR 6.0
- 125 citationsRCR 4.4
- 114 citationsRCR 4.4
- Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.Haematologica · 201276 citationsRCR 2.2
- Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Lancet Haematol · 201576 citationsRCR 2.3
- 65 citationsRCR 1.8
- Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.Lancet Haematol · 201855 citationsRCR 1.9
- Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.Biol Blood Marrow Transplant · 201654 citationsRCR 1.9
- Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.Blood Adv · 201840 citationsRCR 1.6
- Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.Am J Hematol · 202040 citationsRCR 1.8